# Solesence, Inc.: financial statements, quarterly

SLSN · Nasdaq · CIK 883107 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/slsn.md) · [Financials](/companies/slsn/financials.md) · [Filings](/companies/slsn/filings.md) · [Insiders](/companies/slsn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/slsn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [8.0](/filings/0001999371-24-014552.md) | [8.0 d](/filings/0001999371-25-003471.md) | [9.9](/filings/0001999371-25-005991.md) | [13.0](/filings/0001999371-25-011366.md) | [16.9](/filings/0001999371-25-017415.md) | [12.6 d](/filings/0001999371-26-007345.md) | [14.6](/filings/0001999371-26-010555.md) | [20.4](/filings/0001999371-26-018231.md) | [14.6](/filings/0001999371-25-017415.md) | [12.5 d](/filings/0001999371-26-007345.md) | [13.0](/filings/0001999371-26-010555.md) | [15.3](/filings/0001999371-26-018231.md) |
| Cost of revenue | $m | [6.4](/filings/0001999371-24-014552.md) | [7.5 d](/filings/0001999371-25-003471.md) | [6.3](/filings/0001999371-25-005991.md) | [9.3](/filings/0001999371-25-011366.md) | [10.8](/filings/0001999371-25-017415.md) | [9.8 d](/filings/0001999371-26-007345.md) | [11.2](/filings/0001999371-26-010555.md) | [13.9](/filings/0001999371-26-018231.md) | [11.2](/filings/0001999371-25-017415.md) | [9.0 d](/filings/0001999371-26-007345.md) | [9.8](/filings/0001999371-26-018231.md) | [10.6](/filings/0001999371-26-018231.md) |
| Gross profit | $m | [1.5](/filings/0001999371-24-014552.md) | [0.5 d](/filings/0001999371-25-003471.md) | [3.6](/filings/0001999371-25-005991.md) | [3.7](/filings/0001999371-25-011366.md) | [6.1](/filings/0001999371-25-017415.md) | [2.8 d](/filings/0001999371-26-007345.md) | [3.4](/filings/0001999371-26-010555.md) | [6.4](/filings/0001999371-26-018231.md) | [3.4](/filings/0001999371-25-017415.md) | [3.4 d](/filings/0001999371-26-007345.md) | [3.1](/filings/0001999371-26-018231.md) | [4.7](/filings/0001999371-26-018231.md) |
| Research and development | $m | [1.1](/filings/0001999371-24-014552.md) | [0.8 d](/filings/0001999371-25-003471.md) | [0.9](/filings/0001999371-25-005991.md) | [0.9](/filings/0001999371-25-011366.md) | [1.0](/filings/0001999371-25-017415.md) | [1.1 d](/filings/0001999371-26-007345.md) | [1.0](/filings/0001999371-26-010555.md) | [1.0](/filings/0001999371-26-018231.md) | [1.1](/filings/0001999371-25-017415.md) | [1.0 d](/filings/0001999371-26-007345.md) | [1.0](/filings/0001999371-26-018231.md) | [0.9](/filings/0001999371-26-018231.md) |
| Selling, general and administrative | $m | [1.7](/filings/0001999371-24-014552.md) | [1.6 d](/filings/0001999371-25-003471.md) | [1.6](/filings/0001999371-25-005991.md) | [1.8](/filings/0001999371-25-011366.md) | [1.9](/filings/0001999371-25-017415.md) | [1.9 d](/filings/0001999371-26-007345.md) | [2.1](/filings/0001999371-26-010555.md) | [3.0](/filings/0001999371-26-018231.md) | [3.1](/filings/0001999371-25-017415.md) | [2.2 d](/filings/0001999371-26-007345.md) | [2.8](/filings/0001999371-26-018231.md) | [3.7](/filings/0001999371-26-018231.md) |
| Operating income | $m | [(1.2)](/filings/0001999371-24-014552.md) | [(1.9) d](/filings/0001999371-25-003471.md) | [1.1](/filings/0001999371-25-005991.md) | [1.0](/filings/0001999371-25-011366.md) | [3.2](/filings/0001999371-25-017415.md) | [(0.2) d](/filings/0001999371-26-007345.md) | [0.3](/filings/0001999371-26-010555.md) | [2.5](/filings/0001999371-26-018231.md) | [(0.8)](/filings/0001999371-25-017415.md) | [0.2 d](/filings/0001999371-26-007345.md) | [(0.7)](/filings/0001999371-26-018231.md) | [0.1](/filings/0001999371-26-018231.md) |
| Interest expense | $m | [0.2](/filings/0001999371-24-014552.md) | [0.2 d](/filings/0001999371-24-004138.md) | [0.2](/filings/0001999371-24-005984.md) | [0.2](/filings/0001999371-24-009833.md) | [0.2](/filings/0001999371-24-014552.md) | [0.1 d](/filings/0001999371-25-003471.md) | [0.2](/filings/0001999371-25-005991.md) | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.4](/filings/0001999371-26-018231.md) | [0.0 d](/filings/0001999371-25-017415.md) | [(0.3) d](/filings/0001999371-26-007345.md) | not reported | not reported |
| Net income | $m | [(1.4)](/filings/0001999371-24-014552.md) | [(2.1) d](/filings/0001999371-25-003471.md) | [0.9](/filings/0001999371-25-017415.md) | [0.9](/filings/0001999371-25-017415.md) | [3.0](/filings/0001999371-25-017415.md) | [(0.6) d](/filings/0001999371-26-007345.md) | [0.3](/filings/0001999371-26-018231.md) | [3.2](/filings/0001999371-26-018231.md) | [(1.1)](/filings/0001999371-25-017415.md) | [0.2 d](/filings/0001999371-26-007345.md) | [(1.0)](/filings/0001999371-26-018231.md) | [(0.2)](/filings/0001999371-26-018231.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0001999371-24-014552.md) | not reported | [0.02](/filings/0001999371-25-005991.md) | [0.01](/filings/0001999371-25-011366.md) | [0.04](/filings/0001999371-25-017415.md) | not reported | [0.00](/filings/0001999371-26-010555.md) | [0.04](/filings/0001999371-26-018231.md) | [(0.02)](/filings/0001999371-25-017415.md) | not reported | [(0.01)](/filings/0001999371-26-018231.md) | [0.00](/filings/0001999371-26-018231.md) |
| Basic EPS | $ per share | [(0.03)](/filings/0001999371-24-014552.md) | not reported | [0.02](/filings/0001999371-25-005991.md) | [0.02](/filings/0001999371-25-011366.md) | [0.04](/filings/0001999371-25-017415.md) | not reported | [0.00](/filings/0001999371-26-010555.md) | [0.04](/filings/0001999371-26-018231.md) | [(0.02)](/filings/0001999371-25-017415.md) | not reported | [(0.01)](/filings/0001999371-26-018231.md) | [0.00](/filings/0001999371-26-018231.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.2](/filings/0001999371-23-000211.md) | [1.7](/filings/0001999371-25-003471.md) | [2.0](/filings/0001999371-24-005984.md) | [2.4](/filings/0001999371-24-009833.md) | [2.9](/filings/0001999371-24-014552.md) | [1.4](/filings/0001999371-26-007345.md) | [1.8](/filings/0001999371-25-005991.md) | [4.1](/filings/0001999371-25-011366.md) | [0.4](/filings/0001999371-25-017415.md) | [1.3](/filings/0001999371-26-018231.md) | [0.6](/filings/0001999371-26-010555.md) | [1.0](/filings/0001999371-26-018231.md) |
| Current assets | $m | [15.6](/filings/0001999371-23-000211.md) | [16.3](/filings/0001999371-25-003471.md) | [22.1](/filings/0001999371-24-005984.md) | [24.3](/filings/0001999371-24-009833.md) | [29.8](/filings/0001999371-24-014552.md) | [29.3](/filings/0001999371-26-007345.md) | [35.9](/filings/0001999371-25-005991.md) | [38.8](/filings/0001999371-25-011366.md) | [32.8](/filings/0001999371-25-017415.md) | [25.2](/filings/0001999371-26-018231.md) | [22.7](/filings/0001999371-26-018231.md) | [25.3](/filings/0001999371-26-018231.md) |
| Total assets | $m | [32.3](/filings/0001999371-23-000211.md) | [32.9](/filings/0001999371-25-003471.md) | [38.5](/filings/0001999371-24-005984.md) | [40.8](/filings/0001999371-24-009833.md) | [48.0](/filings/0001999371-24-014552.md) | [50.0](/filings/0001999371-26-007345.md) | [57.0](/filings/0001999371-25-005991.md) | [60.0](/filings/0001999371-25-011366.md) | [54.0](/filings/0001999371-25-017415.md) | [46.5](/filings/0001999371-26-018231.md) | [44.1](/filings/0001999371-26-018231.md) | [46.4](/filings/0001999371-26-018231.md) |
| Current liabilities | $m | [17.7](/filings/0001999371-23-000211.md) | [15.6](/filings/0001999371-25-003471.md) | [12.2](/filings/0001999371-24-005984.md) | [13.8](/filings/0001999371-24-009833.md) | [23.3](/filings/0001999371-24-014552.md) | [25.8](/filings/0001999371-26-007345.md) | [32.9](/filings/0001999371-25-005991.md) | [22.5](/filings/0001999371-25-011366.md) | [17.9](/filings/0001999371-25-017415.md) | [13.9](/filings/0001999371-26-018231.md) | [12.7](/filings/0001999371-26-010555.md) | [26.0](/filings/0001999371-26-018231.md) |
| Long-term debt | $m | [1.0](/filings/0001999371-23-000211.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [3.9](/filings/0001999371-24-014552.md) | [1.9](/filings/0001999371-26-007345.md) | [5.0](/filings/0001999371-25-017415.md) | [11.9](/filings/0001999371-25-017415.md) | [15.2](/filings/0001999371-25-017415.md) | [10.4](/filings/0001999371-26-018231.md) | [10.8](/filings/0001999371-26-018231.md) | [14.4](/filings/0001999371-26-018231.md) | [17.2](/filings/0001999371-25-017415.md) | [14.1](/filings/0001999371-26-018231.md) | [13.2](/filings/0001999371-26-018231.md) | [13.2](/filings/0001999371-26-018231.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [2,605 d](/filings/0001999371-24-014552.md) | [(2,650) d](/filings/0001999371-25-003471.md) | [(3,855)](/filings/0001999371-25-005991.md) | [(565) d](/filings/0001999371-25-011366.md) | [4,202 d](/filings/0001999371-25-017415.md) | [2,189 d](/filings/0001999371-26-007345.md) | [(7,221)](/filings/0001999371-26-010555.md) | [(654) d](/filings/0001999371-26-018231.md) | [(2,511) d](/filings/0001999371-25-017415.md) | [1,819 d](/filings/0001999371-26-007345.md) | [1,517](/filings/0001999371-26-010555.md) | [191 d](/filings/0001999371-26-018231.md) |
| Capital expenditure | $k | [41.0 d](/filings/0001999371-24-014552.md) | [199 d](/filings/0001999371-25-003471.md) | [85.0](/filings/0001999371-24-005984.md) | [477 d](/filings/0001999371-24-009833.md) | [1,403 d](/filings/0001999371-24-014552.md) | [2,593 d](/filings/0001999371-25-003471.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [49.2](/filings/0001999371-23-000211.md) | [49.4](/filings/0001999371-24-005984.md) | [50.1](/filings/0001999371-24-009833.md) | [49.6](/filings/0001999371-24-014552.md) | [58.0](/filings/0001999371-25-005991.md) | [58.7](/filings/0001999371-25-011366.md) | [71.9](/filings/0001999371-25-017415.md) | [72.6](/filings/0001999371-26-010555.md) | [72.6](/filings/0001999371-26-018231.md) | [70.5](/filings/0001999371-25-017415.md) | [70.6](/filings/0001999371-26-010555.md) | [70.6](/filings/0001999371-26-018231.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 70,647,045 at 2026-08-19, from the cover of the [10-Q filed 2026-08-19](/filings/0001999371-26-018231.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.